← Back to Clinical Trials
Recruiting NCT07056023

NCT07056023 Multicenter Trial on Surgical Outcome and Quality of Life in Juxta-medullary Tumors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07056023
Status Recruiting
Phase
Sponsor University Hospital Muenster
Condition Intraspinal Tumor
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2025-05-01
Primary Completion 2027-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2025-05-01 with a primary completion date of 2027-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Primary objectives: Primary objectives are to assess and define benchmarks of the surgical outcome in the form of extent of resection, functionality, and quality of life after resection of juxta medullary tumors Secondary objectives: Assessment of variables leading to better outcome through regression analysis: 1. Influence of surgical approach on functionality, pain, and quality of life 2. Comparison between patient with severe neurological (McCormick scale 3-5) to patients with mild deficits (McCormick scale 1-2) 3. Role of intraoperative monitoring (IOM) in extent of resection and neurological deficits Assessment of treatment variations: 1. Assessment of risk factors for incomplete resection 2. Non inferiority of unilateral approach to achieve gross total resection of spinal meningioma, schwannoma and cauda ependymoma 3. Role of bed rest after surgery to prevent cerebro-spinal fluid leakage 4. Influence of laminectomy on cerebro-spinal fluid leakage Quality indicators: assessments of length of hospital stay, 30- and 90-days re-admissions, 30- and 90-days re-surgery, nosocomial infections

Eligibility Criteria

Inclusion Criteria: * Adult, age ≥18 years, patients treated on intraspinal, extra medullary tumor * Patients must have sufficient cognitive and language skills to give informed consent Exclusion Criteria: * Absence of informed consent * Lack of ability to consent * Primary bone tumors invading the intra-spinal space * Vertebral metastasis

Contact & Investigator

Central Contact

Michael Schwake, MD

✉ schwakem@uni-muenster.de

📞 +49 251 8343930

Frequently Asked Questions

Who can join the NCT07056023 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Intraspinal Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07056023 currently recruiting?

Yes, NCT07056023 is actively recruiting participants. Contact the research team at schwakem@uni-muenster.de for enrollment information.

Where is the NCT07056023 trial being conducted?

This trial is being conducted at Münster, Germany.

Who is sponsoring the NCT07056023 clinical trial?

NCT07056023 is sponsored by University Hospital Muenster. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology